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Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of polycystic kidney disease that presents
primarily in infancy and childhood and that is characterized by enlarged kidneys and congenital hepatic fibrosis.
We have identified PKHD1, the gene mutated in ARPKD. PKHD1 extends over 469 kb, is primarily expressed
in human fetal and adult kidney, and includes a minimum of 86 exons that are variably assembled into a number
of alternatively spliced transcripts. The longest continuous open reading frame encodes a 4,074-amino-acid protein,
polyductin, that is predicted to have a single transmembrane (TM)-spanning domain near its carboxyl terminus,
immunoglobulin-like plexin-transcription–factor domains, and parallel beta-helix 1 repeats in its amino terminus.
Several transcripts encode truncated products that lack the TM and that may be secreted if translated. The PKHD1-
gene products are members of a novel class of proteins that share structural features with hepatocyte growth-factor
receptor and plexins and that belong to a superfamily of proteins involved in regulation of cell proliferation and
of cellular adhesion and repulsion.
Introduction
Autosomal recessive polycystic kidney disease (ARPKD
[MIM 263200]) is a hereditary and severe form of poly-
cystic kidney disease affecting the kidneys and biliary
tract, with an estimated incidence of 1/20,000 live births
(Zerres et al. 1998). The clinical spectrum is widely var-
iable, with most cases presenting during infancy (Guay-
Woodford 1996). The human fetal phenotypic features
classically include enlarged and echogenic kidneys, aswell
as oligohydramnios secondary to a poor urine output
(Reuss et al. 1990). Up to 50% of the affected neonates
die shortly after birth, as a result of severe pulmonary
hypoplasia and secondary respiratory insufficiency.Those
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who survive the perinatal period express widely variable
disease phenotypes. In the subset that survived the peri-
natal period, morbidity and mortality are mainly related
to severe systemic hypertension, renal insufficiency, and
portal hypertension due to portal-tract fibrosis (Zerres et
al. 1996).
Mutations at a single locus, PKHD1 (polycystic kid-
ney and hepatic disease 1), are responsible for all typical
forms of ARPKD. In previous studies, we have mapped
PKHD1 to 6p21.1-p12 (Zerres et al. 1994; Guay-
Woodford et al. 1995). We subsequently constructed a
series of physical and genetic maps that refine the lo-
calization of PKHD1 to a candidate region of ∼1 cM,
delimited by D6S1714 and D6S1024 as the telomeric
and centromeric flanking markers, respectively (Lens et
al. 1997; Mucher et al. 1998; Park et al. 1999). More-
recent recombination-mapping studies have further re-
duced the size of the interval, to 834 kb, with KIAA0057
(CA)28 as the new centromeric boundary (Onuchic et
al., in press).
In the present study, we describe the identification of
PKHD1, a novel gene encoded in a minimum of 86
exons that are assembled in a complex pattern of al-
ternative splice variants. The predicted translation prod-
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ucts are novel proteins that share homology to a su-
perfamily of proteins involved in the regulation of cell
proliferation and of cellular adhesion and repulsion.
Patients, Material, and Methods
Patients and Samples
The databases of patients used in this study are from
University of Alabama at Birmingham and Rheinisch-
Westfa¨lische Technische Hochschule (Aachen, Germany).
The diagnostic criteria were the same as those reported
elsewhere (Zerres et al. 1998). The group of patients stud-
ied had clinical features representative of the entire
ARPKD clinical spectrum. Pedigrees were recruited, and
blood samples were obtained, with informed consent by
the patients with ARPKD and by members of their fam-
ilies. Control DNA from 40 individuals also was obtained
after informed consent had been given, and an additional
20 control DNA samples were purchased from theCoriell
Cell Repository. DNA was extracted as described else-
where (Eggermann et al. 1993).
Transcription Map
Database searches included a systematic surveillance of
the UniGene, Sanger (see the Human Sequence DataWeb
site), TIGR (see the Tigr DatabasesWeb site), Celera (pub-
lic domain), and GenBank OverviewWeb sites. The gene-
prediction algorithms FGenesh (see the Nucleotide Se-
quence Analysis Web site) (Salamov and Solovyev 2000)
and GENSCAN (Burset and Guigo 1996; Burge and Kar-
lin 1997) were used to annotate genomic sequence as it
became available. Expressed sequences were confirmed
by RT-PCR across putative splice junctions, with human
adult kidney mRNA as template, by PCR-amplification
using a panel ofmultiple-tissue cDNAsamples as template
(Origene) and by northern blot analysis using humanmul-
tiple-tissue blots (Clontech).
PKHD1 cDNA Isolation
Most of the PKHD1 cDNA products were amplified
with human adult kidney double-stranded cDNA (Mar-
athon Ready cDNA, Clontech) used as template. A sec-
ond set of products were generated by RT-PCR using
either 20 ng of human adult kidney mRNA (Clontech)
or 1.5–4.0 mg of human adult kidney total RNA as tem-
plate. The total RNA was extracted by Trizol reagent
(Invitrogen) and was reverse transcribed by random hex-
amer primers and Superscript reverse transcriptase
(Gibco BRL). A third set of cDNA products was am-
plified by a 1:20 dilution of an oligo-dT–primed human
adult kidney cDNA library (Gibco/BRL). The 5′ RACE
and 3′ RACE experiments were performed according to
the manufacturer’s instructions (Clontech). (Primer se-
quences used to amplify the set of cDNA products are
listed in table A1, in the Appendix published in the on-
line version of this article.)
Mutation Detection
PCR primers flanking individual exons and offset, by
∼20 bp, from intron-exon junctions were designed by the
program Primer3 and were used to amplify 20 ng of ge-
nomic DNA from patients and controls. In cases of exons
1400 bp, several overlapping primers were designed to
ensure that the size of the amplicons remained !500 bp.
(All primer sequences used are listed in table A2, in the
Appendix published in the online version of this article.)
Mutation detection was performed by the Transgenomic
Wave denaturing high-performance liquid-chromatogra-
phy system (DHPLC) (Transgenomic). PCR products
were denatured at 98C for 4 min and were allowed to
reanneal; 8–12 ml of each amplicon were injected into
the column and were eluted with a linear acetonitrile gra-
dient, at a flow rate of 0.9 ml/min. The mobile phase
consisted of a mixture of buffers A (0.1 M triethylam-
monium acetate and 1 mM EDTA) and B (25% aceton-
itrile in 0.1 M triethylammonium acetate). The buffer
gradient for each amplicon was determined according to
Wavemaker version 3.3 (and, subsequently, version 4.1)
(Transgenomic) system-control software. The optimum
denaturing temperature required for successful resolution
of heteroduplexes was also determined by this software.
If the resolution of the DHPLC profile was not adequate,
a second temperature, typically either 2C above or below
the first temperature, was used to improve resolution.
Samples showing altered elusion properties not present in
controls were sequenced in both directions, and sequence
variations were identified by visual inspection and com-
parison of the resulting electropherograms. When ampli-
cons had altered elution properties in both control and
patient DNA, they were sequenced in both samples, to
confirm their identity at the sequence level.
Sequence Analysis and Protein Modeling
The genomic structure and the gene orientation were
established by alignment of the confirmed expressed se-
quences and the interval genomic sequence, by BLAST2
(see the BLAST Web site). Sequence homologies were
identified by the BLASTP/N/X programs (see the BLAST
Web site). SMART (simple modular architecture research
tool (Schultz et al. 1998; Letunic et al. 2002) and PRO-
SITE (see the ExPASy Molecular Biology Server Web site)
were used to identify domain architecture and protein
motifs. All analyses were performed with the default
parameters.
Northern Blot Analysis
Probes were amplified by use of cloned gene frag-
ments as template. PCR products were gel purified, [32P]-
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labeled by the multiprime method, and hybridized to
human adult and human fetal MTN blots (Clontech).
Hybridizations were performed at either 68C, with
ExpressHyb (Clontech), or 42C, with a formamide-
based buffer, and were washed under stringent condi-
tions (68C for 1 h, in 0.1 SSC, 0.1% SDS). Images were
obtained by a PhosphorImager (Molecular Dynamics).
Results
Transcription Map of the Minimal Interval
We assembled a transcription map of the minimal in-
terval, using database searches, cDNA-library screening,
genomic-sequence annotation with gene structure–pre-
diction programs, RT-PCR, and northern blot analyses.
A total of 35 nonoverlapping sets of genes, cDNA clones,
ESTs, and RT-PCR products were mapped to the critical
region (fig. 1A). The genes KIAA0057 (Onuchic et al.
1999), FLJ10466 (Onuchic et al., in press),MCM3 (Hof-
mann et al. 2000), Interleukin-17 (Rouvier et al. 1993),
and ML-1 (Kawaguchi et al. 2001) have been described
elsewhere. Each of these genes either has been excluded
as a candidate for PKHD1 or, on the basis of its known
function, has been deemed to be an unlikely candidate.
Transcripts with kidney expression were preferentially
targeted for mutation analysis. One such transcript, a
novel 1.82-kb expressed sequence, Gene Unit 442L12,
identified by gene structure–prediction programs and con-
firmed by RT-PCR from kidney mRNA, mapped to BAC
442L12, within the distal portion of the critical interval
(fig. 1B and C). A second novel transcript of 1.03 kb
(Gene Unit 6), initially identified by similar methods and
mapped to BACs 771D21 and 374E4 (fig. 1B and C),
was subsequently found to share some, although not all,
of its exons with both transcript hCT1642763 (Venter et
al. 2001) and a single human EST (BF822430) derived
from a kidney tumor library; Gene Unit 6 appeared to
have a mouse ortholog in UniGene cluster Mm.25855,
comprised of ESTs obtained from kidney and liver
libraries.
The PKHD1 Transcript and Genomic Organization
As putative expressed sequences were identified in the
PKHD1 region, they were systematically analyzed for
mutations, by screening, by DHPLC, of 20 unrelated
affected patients and 20 normal controls (see below).
Virtually simultaneously, we discovered, in Gene Unit 6
and Gene Unit 442L12, two apparently unrelated ex-
pressed sequences, variants that appeared only in the
samples from our patients and not in samples from the
controls. Among hundreds of amplicons analyzed in the
region up to that point, none had given a pattern of
variation exclusive to affected individuals. We analyzed
an additional 40 control individuals, to confirm that
neither of these variants was present in 120 control chro-
mosomes. Subsequent RT-PCR studies using kidney
mRNA as template established that Gene Unit 6 and
Gene Unit 442L12 are part of the same gene. We went
on to determine both the structure of the complete tran-
script and its genomic organization.
Northern blot analyses (fig. 2) suggested that the
PKHD1 transcript was considerably longer and involved
more complex splicing variations than was initially sug-
gested by the Gene Unit 6 and Gene Unit 442L12 tran-
scripts.We used a PCR-based approachwith primers stra-
tegically positioned within Gene Unit 6 and Gene Unit
442L12 to determine the sequence of the longest open
reading frame (ORF) of PKHD1, to elucidate its genomic
structure and to define the complex pattern of exon as-
sembly. Human kidney RNA, an human adult kidney
cDNA library and human adult kidney double-stranded
cDNAwere used as templates (fig. 3). A number of primer
combinations and end-clone amplifications, as well as 5′
RACE and 3′ RACE reactions, were required to establish
the composite sequence of the full length gene (for the
complete sequence, see fig. A1, in the Appendix published
in the online version of this article). A human adult kidney
cDNA library, human kidney mRNA and total RNA and
double-stranded cDNA served as templates for these stud-
ies. The sequences of all exons and splicing junctionswere
determined both by double strand sequencing of PCR
products and by comparison with the publicly available
genomic sequence of the interval (fig. 3).
These studies provided rigorous confirmation that the
Gene Unit 6 and Gene Unit 442L12 were part of the
same gene, but they also yielded a number of unantic-
ipated results. We discovered that hCT1646988 (Venter
et al. 2001), previously reported as an independent gene,
was actually part of PKHD1. However, regardless of
method used, we were not successful in linking the last
three exons of hCT1646988 to the remainder of the
PKHD1 transcript. We encountered similar problems
with hCT1642763, as RT-PCR, cDNA amplification,
and 5′ RACE could not confirm the existence of exons
1–3 within the PKHD1 transcript. These same methods
did, however, identify two previously unknown exons
at the putative 5′ end of PKHD1, one of which contained
the predicted translation start site. We also identified a
small number of errors in the sequence available in pub-
lic databases. Although most were relatively minor, one
would be predicted to alter the reading frame of the
protein. We have verified the accuracy of our sequence
for the regions in question by determining the sequence
of both DNA strands in several templates.
These data indicate that PKHD1 spans 469 kb of
genomic sequence and, possibly—if the unverified 5′ and
3′ exons of hCT1642763 and hCT1646988, respectively,
are included—as much as 643 kb. These results also
show that the 3′ end of PKHD1 is positioned 74-kb
Figure 1 Chromosomal localization and genomic organization of PKHD1. A, Schematic representation of chromosome 6p12. Currently
known genes are identified on the far left (italics), and STSs/polymorphic markers are on the right. The closest flanking genetic markers that
define the minimal PKHD1 interval are indicated (boldface). Not all of the 35 overlapping sets of expressed sequences described in the text
are shown. B, Genomic organization of PKHD1. Exons identified by numbers have been shown to be part of PKHD1 transcripts. Letters
indicate exons that belong to either hCT1642763 or hCT1646988 and that have not been confirmed by our analyses. The black diamond ()
identifies, in hCT1642763 and hCT1646988, overlapping exons whose boundaries differ from those used in the present study. Arrows indicate
the positions of the Gene Unit 6 and Gene Unit 442L12 transcripts described in the text. C, BACs and PACs sequenced by the Sanger Centre
that cover the interval.
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Figure 2 PKHD1 expression profile. A, Human adult multiple-
tissue northern blot probed with PKHD1 exon 59: lane 1, pancreas;
lane 2, kidney; lane 3, skeletal muscle; lane 4, liver; lane 5, lung; lane
6, placenta; lane 7, brain; lane 8, heart. B, Same blot as in panel A,
probed with PKD1. The arrow indicates the position of a known
splicing variant of PKD1. C, Human fetal multiple-tissue northern
blot probed with PKHD1: lane, 1, kidney; lane 2, liver; lane 3, lung;
lane 4, brain. D, Same blot as in panel C, probed with PKD1.
distal to the flanking genetic marker, D6S1714 (fig. 1),
thus explaining why we found so few meiotic recom-
binations between this marker and the disease pheno-
type. The total number of exons that we identified in
PKHD1 transcripts is 86 (fig. 3B). This may be a con-
servative estimate, since it is likely that at least some of
the unverified exons in either hCT1642763 (exons 1–3,
9, 19, 23, 32, and 33), hCT1646988 (exons 9–11) or
the EST database or predicted by computer algorithms
will ultimately be experimentally confirmed if mRNA or
cDNA from a suitable tissue is used as template.
In our attempt to assemble a complete cDNA, we
identified a large number of distinct transcripts that had
unique combinations of PKHD1 exons. Representative
examples are presented in figure 3B. The absolute num-
ber of differentially spliced products is almost certainly
higher, since we did not perform an exhaustive analysis
of every primer combination. In numerous cases, a PCR
reaction that appeared to yield a single amplification
product was discovered, after cloning and sequencing,
to include multiple, differentially spliced products of
nearly identical size. We believe that these data provide
a likely molecular explanation for the lack of a discrete
message seen, in northern blot analysis, with labeled
PKHD1-gene segments (fig. 2).
Mutation Analyses
We performed mutation detection by using DHPLC
across the 67 exons comprising the longest potential
ORF (figs. 3 and 4; primer sequences used to amplify
the set of cDNA products are listed in table A2 in the
Appendix, published in the online version of this article).
We expanded our patient group to 25 individuals (50
disease chromosomes) and our control group to 60 in-
dividuals (120 chromosomes). We focused most of our
mutation-detection efforts on individuals for whom we
had family material enabling us to confirm segregation
of alleles. The patients represented diverse nationalities
and the complete spectrum of clinical disease (table 1).
In all cases in which segregation could be established,
the mutant alleles resided on separate chromosomes
(fig. 4A). A minimum of 67 exons (longest ORF) was
screened in each individual, and, in all cases, either 0,
1, or 2 putative pathogenic variants were found. We
identified potentially pathogenic variants in 21 (42%)
of 50 disease chromosomes; these were defined as var-
iants detected in patients by DHPLC and confirmed by
sequencing and not observed by DHPLC in any of the
120 control chromosomes. The finding of these mu-
tations establishes this gene as PKHD1 (table 1).
Eight different nonconservative missense changes ac-
counted for mutations in 12 of 21 disease chromosomes
for which we found mutations. Among these, 9415GrT
(D3139Y) corresponded to the initial variant discovered
in Gene Unit 442L12, and 107CrT (T36M) corre-
sponded to the initial variant found in Gene Unit 6; six
different frameshifting mutations accounted for the re-
maining 9 disease chromosomes. One individual, 340/
1395 (table 1 and fig. 4), had frameshifting mutations in
both alleles. This individual provides perhaps the clearest
proof of that we have identified PKHD1. This finding is
also the most consistent with the notion that PKHD1
causes disease by a loss-of-function mechanism. One fra-
meshifting variant, 5895_5896insA, occurred in three un-
related individuals (AL36, AL 48, and 340/1395). Two
missense variants also recurred: variant 664ArG (I222V)
was seen in two individuals who were not known to be
related and who are of distinct national origins; variant
4870CrT (R1624W), on the other hand, was identified
in a family with known consanguinity and in two other
individuals from the same geographical region. This var-
iant may represent a founder allele in this population.
With the exception of the consanguineous family, all other
individuals are compound heterozygous for mutations in
which both variants were identified. In individuals in
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Figure 3 Structure of full-length PKHD1 and its splicing variants. A, Set of 71 nonoverlapping exons that spans the entire length of
PKHD1 (upper row) and 15 additional overlapping exons that use different splice sites (gray boxes, lower row). Exons, which are not present
in the cDNA that encodes the longest ORF, are indicated by hatched boxes. The position of important protein domains is indicated. B,
Approximate location of each primer set used to amplify various cDNAs, with representative set of amplified products (below each schema).
White boxes indicate noncoding exons in the corresponding transcripts while gray boxes identify exons with alternative boundaries (A). The
templates used for each amplification are as follows: human adult kidney double-stranded cDNA for primer sets 1–4, 6, and 8; human kidney
mRNA and total RNA for primer sets 5 and 7; human adult kidney cDNA library for primer set 9. “SC” indicates approximate location of
stop codons, and “ORF” indicates that an open reading frame extends throughout the length of the fragment. C, Longest ORF identified by
RT-PCR/cDNA amplification. This ORF is the composite sequence of products 2.1 and 4.1 of panel B and includes a total of 67 exons.
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Figure 4 PKHD1 mutations in families studied. A, Representative family-segregation analyses of PKHD1 mutations for patients AL 1,
AL 11, AL 36, AL 48, AL 52, and 340/1395 (see table 1). Sequence electropherograms showing wild-type and mutant sequences for amplicons
containing the respective variants in each family are indicated on the right of each pedigree figure. Traces labeled “mutant” show heterozygous
alterations in genomic PCR products. Segregation of the mutant allele (denoted by “Ex” followed by the exon number) is shown for each
kindred studied. AL 1 has two missense changes, whereas AL 11, AL 36, and AL 48 each have a missense and a frameshifting mutation. Patient
340/1395 has two frameshifting mutations. AL 52 and her sibling, products of a consanguineous union, are homozygous for the Ex32 mutation
(trace labeled AL 52). The Ex32 trace labeled “mutant” is from the heterozygous father. Black symbols denote affected individuals; white
symbols denote unaffected individuals. B, Representative DHPLC profiles for several sequence variants in families with PKHD1 (see panel A
and table 1). Black traces indicate control profiles; red traces indicate patient variant profiles (the red trace is displaced upward to facilitate
comparison).
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Table 1
Mutations in PKHD1
Patient (ARPKD Phenotype) and Nucleotide (ORF) Changea Exonb
Parent in Whom
Variant Is Identified Country
AL 1 (later onset):
107CrT (T36M) 3 Father United States
664ArG (I222V) 9 Mother
AL 11 (perinatal onset):
3761_3762delCCinsG (A1254Xfs1302) 32 Father United States
3364GrA (G1122S) 29 Mother
AL 18 (later onset):
8829_8830insC (I2944Xfs2949) 58 Father South Africa (Afrikaner)
664ArG (I222V) 9 Mother
AL 36 (perinatal onset):
8870TrC (I2957T) 58 Father United States
5895_5896insA (L1966Xfs1969) 36 Mother
AL 45 (later onset):
4870CrT (R1624W) 32 Father Saudi Arabia
AL 47 (later onset):
2279GrA (R760H) 22 Father Saudi Arabia
4870CrT (R1624W) 32 Mother
AL 48 (later onset):
5895_5896insA (L1966Xfs1969) 36 Father United States
757TrC (F253L) 11 Mother
AL 52 (later onset):c
4870CrT (R1624W) 32 Father Saudi Arabia
4870CrT (R1624W) 32 Mother
376/1559 (perinatal onset):
1620_1621insAGTT (E541Xfs556) 18 Father Germany
9415GrT (D3139Y) 59 Mother
340/1395 (perinatal onset):
711_714delAATG (S237Xfs244) 11 Father United Kingdom
5895_5896insA (L1966Xfs1969) 36 Mother
306/1272 (unknown):
10075delG (G3359Xfs3399) 61 Mother Turkey
291/1207 (later onset):
3306delT (Y1102X) 29 Mother Turkey
a Nucleotide and codon numbers are based on the predicted 67-exon transcript of the longest ORF (fig. 3C; also see
figs. A1 and A2 in the Appendix, published in the online version of this article). Nomenclature for the description of
sequence variations is from the Nomenclature for the Description of Sequence Variations Web site. None of these variants
were identified in 120 control chromosomes.
b Based on 71 exons shown in figure 3A.
c Consanguineous union.
whom only one or no mutations were found, it is likely
that the DHPLC mutation screen as applied has failed to
detect the second (or either) variant.
Expression Features of PKHD1
Commercially acquired human adult and human fetal
multiple-tissue northern blots were hybridized with two
different probes (exon 59 and exons 66–70; fig. 3A), to
determine the expression pattern of PKHD1. Rather
than a single, discrete message, both probes detected a
smear that ranged from ∼8.5 kb to ∼13 kb (fig. 2). The
highest level of expression was observed in the human
fetal and human adult kidney samples, consistent with
a role of this gene in kidney development and function.
In the human adult specimen, the peak signal was ob-
served as two diffuse bands, of ∼9 kb and ∼12 kb. In
human fetal kidney, the size distribution of the tran-
scripts appeared to be somewhat lower and more uni-
form. PKHD1 is also present in the pancreas, but at
much lower levels. PKHD1 is barely detectable in human
fetal and human adult liver. The remaining tissue sam-
ples had no visible signal. Given the diffuse signal from
the transcripts, however, we cannot exclude a low level
of expression in other organs. When the identical blots
were hybridized with a probe recognizing exons 43–46
of human PKD1, discrete, high-molecular-weight bands
of the correct size were produced, excluding nonspecific
degradation of high-molecular-weight mRNA in the
samples as being an explanation for the PKHD1 results
in northern blot analysis.
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Figure 5 Structure of polyductin and related proteins. Multiple
tandemly repeated IPT domains are common features of the group.
Polyductin-M shares the general structure of the HGFR and plexin
A3, in having a long extracellular domain, a single TM domain, and
a short cytoplasmic carboxyl terminus, whereas polyductin-S is more
like D86.
The PKHD1 Product: a Membrane-Anchored Protein
with Multiple Immunoglobulin-Like Plexin-Transcription
Factor (IPT) Domains (SMART Accession Number
SM0429) and Parallel Beta-Helix 1 (PbH1) Repeats
(SMART Accession Number SM0710)
The composite cDNA that yielded the longest contin-
uous ORF, experimentally amplified, from kidney cDNA,
as two overlapping fragments (fig. 3B), is 12.6 kb in
length, includes 67 exons, and is predicted to encode a
protein of 4,074 amino acids (for the complete sequence
of amino acids, see fig. A2 in the Appendix, published in
the online version of this article). This novel protein,
which we have named “polyductin,” is predicted, by
SMART, to be an integral membrane protein with a
3,858-amino-acid extracellular amino terminus, a single
transmembrane (TM)-spanning domain , and a short car-
boxyl terminus (fig. 5).
BLASTP (see the BLAST Web site) analysis revealed
that polyductin has highest homology to murine protein
D86. The region of homology begins near the amino ter-
minus of both molecules and stretches over most of the
entire length (1,944 amino acids) of D86. The function
of D86 is not known, but it is described, in GenBank, as
a novel protein secreted from lymphocytes (see the
GenBank Overview Web site). Significant homologies
were also observed for two expressed sequences,
KIAA1412 and TM protein 2 (accession number
AAF21348 [see the Nomenclature for the Description of
Sequence Variations Web site]), that encode identical
novel proteins of unknown function (Nagase et al. 2000;
Scott et al. 2000).
Several short segments of polyductin have weak ho-
mology to other proteins whose functions are known,
including the hepatocyte growth-factor receptor (HGFR
[accession number P08581]) and several plexins. Using
SMART, we determined that these sequences encode IPT
domains. The structure of several IPT-containing pro-
teins has been determined (Cramer et al. 1997), but their
function remains unknown. IPT domains consist of an
immunoglobulin-like fold, and proteins that contain IPT
domains generally belong to one of two classes: intra-
cellular DNA transcription factors (the Rel family) or
single-pass cell-surface receptors that are members of the
Sema superfamily of proteins (i.e., HGFR, Ron, and the
large family of plexins). Although all members of the
Rel family have a single IPT unit that is involved in DNA
binding, virtually all of the receptor proteins contain
multiple IPT domains, often tandemly arranged. Topol-
ogy predictions indicate that polyductin contains six IPT
domains within its extracellular segment (fig. 5). The
overall similarity between polyductin and receptor mol-
ecules such as HGFR and plexin A3 (accession number
P51805 [see the Nomenclature for the Description of
Sequence Variations Web site]) suggests a similar func-
tion for polyductin. However, there are differences in
structure that suggest that polyductin is unique. Polyduc-
tin lacks the Sema domain (SMART accession number
SM0630) and the plexin/semaphorin/integrin (PSI) do-
main (SMART accession number SM0423), which are
common to all other members of the Sema superfamily.
It also lacks (a) an intracellular kinase domain present
in HGFR and (b) other conserved cytoplasmic sequences
present in plexin subclasses.
SMART analysis identified a second motif within
polyductin, a motif that might provide additional func-
tional clues. The program revealed a minimum of 9
(and, possibly, 10) PbH1 repeats clustered within three
groups between the last IPT domain and the TM do-
main (fig. 5). PbH1 repeats are most commonly asso-
ciated with polysaccharidases, and, within this enzyme
class, bacterial polysaccharidases are the most exten-
sively studied. These bacterial enzymes serve as im-
portant virulence factors for plant pathogens, since
they allow bacteria to degrade plant cell-wall polysac-
charides. The PbH1 repeats are essential for enzyme
function, forming both the ligand-binding and catalytic
sites. The presence of multiple PbH1 domains within
polyductin suggests that polyductin may have similar
catalytic properties.
Motif analysis by the PROSITE program identified
multiple potential N-glycosylation sites and a single
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arginine-glycine-aspartate (RGD) domain. This motif
is found in fibronectin and numerous other proteins,
where it has been shown to play a role in cell adhesion.
In addition, three putative cAMP/cGMP phosphory-
lation sites were identified within the cytoplasmic car-
boxyl terminus. No tyrosine phosphorylation consen-
sus sites were recognized within this cytoplasmic tail,
further distinguishing between polyductin and mem-
bers of the plexin family.
Finally, we examined how the various splicing ar-
rangements might affect the protein(s) structure. If, in
fact, some of the alternatively spliced products are also
translated, then the gene products are predicted to fall
into two broad groups: one group, which includes the
longest continuous ORF but which may also include
molecules lacking some middle domains, has a single
TM element and is likely to be associated with the
plasma membrane (polyductin-M); the other group
lacks a TM domain, and thus its members may be se-
creted (polyductin-S) (fig. 5).
Discussion
We have reported here the initial description and char-
acterization of a novel gene, PKHD1, implicated in all
typical forms of ARPKD. Multiple lines of evidence
strongly support the pathogenic role that mutations in
this gene play in ARPKD. First, the genomic structure
of this candidate extends over nearly 50% of the critical
PKHD1 interval defined by recombination mapping.
This observation alone provides a high prior probability
that this gene is the disease-susceptibility locus. Second,
this gene is expressed predominantly in the kidney, an
organ invariably involved in this disorder. Third, we
have identified a large number of protein-truncatingmu-
tations and missense variants that are found only in af-
fected individuals and not in a large number of controls.
For individuals in whom we have identified two muta-
tions, we have shown that the mutations occur on sep-
arate haplotypes and that they segregate with the disease
chromosomes. In no case did we identify an individual
who had more than two putative pathogenic variants.
The panel of patient material used included both the
severe perinatal and milder, later-onset disease pheno-
types (table 1). The limited sample size leaves open any
conclusions regarding genotype-phenotype correlations,
but it does permit a few preliminary hypotheses. Among
individuals in whom both mutations were identified, the
only individual with two chain-terminating mutations
(i.e., individual 340/1395) had the severe phenotype.
The three individuals with missense mutations on both
alleles (i.e., individuals AL 1, AL 47, and AL 52) had
the later-onset phenotype. Of the five individuals with
both a chain-terminating frameshifting mutation and a
missense mutation, two had the later-onset phenotype,
and three had the severe phenotype; none shared the
same missense allele. It is possible that not all missense
variants are functionally equivalent—some may result
in hypomorphic alleles that allow for a clinically milder
course. An expanded study of genotype-phenotype
correlations should clarify this point. In light of the
complex splicing pattern and multiple transcripts,
identification of pathogenic mutations is one means of
identifying those exons whose presence in a transcript
is essential for the function of PKHD1 in the kidney
and liver. The current analysis suggests that exons 3,
9, 11,18, 22, 29, 32, 36, 58, 59, and 61 (of the 67
exons in the longest ORF) are essential for normal
polyductin function. These data also highlight the lack
of evidence for clustering of mutations either in any
one region of the gene or in any functional domain of
the putative protein.
The PKHD1 gene and its translation products have
several distinctive features that warrant special note.
First, with a genomic size of469 kb, PKHD1 is among
the largest human genes characterized to date. Second,
the gene encodes a complex and extensive array of splice
variants discovered by RT-PCR and cDNA cloning and
confirmed by northern blot analysis. We excluded the
possibility that the diffuse signal observed on northern
blots results from degradation of RNA, by the presence
of an intact 14-kb PKD1 transcript on the same blots.
Moreover, the multiplicity of different transcripts dis-
covered in public databases, revealed by RT-PCR of
kidney mRNA, and amplified from aliquots of double-
stranded cDNA as well as provided by a cDNA library,
correlates well with the results of northern blot analysis.
It is important to note that almost all of the exons
exhibit consensus donor and acceptor splice sites, fur-
ther supporting the conclusion that these are legitimate
transcripts.
The multiplicity of splicing variants observed for
PKHD1 is an uncommon feature of mammalian genes.
Preliminary studies of mouse tissue suggest that the
complicated splicing pattern is likely conserved (Y.N.,
unpublished observations), indicating a functional role
for this property. The abundance of these splice vari-
ants in poly-A–enriched samples indicates that many,
if not all, are fully processed to include a poly-A tail.
It is not presently known how many of the transcripts
are actually translated into protein. In the event that
most of the mRNAs are translated, it could mean that
this single gene might encode numerous distinct pol-
ypeptides. Similar findings have been reported for the
neurexin family of genes (Missler and Sudhof 1998).
Just three genes may encode 11,000 isoforms that,
through alternative splicing, differ in size and amino
acid sequence. Interestingly, the general structure of
the largest gene products is similar to that of polyduc-
tin-M. Likewise, a subset of the transcripts is predicted
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to contain stop codons and to produce secreted pro-
teins without a TM region. The neurexin family of
proteins is expressed in neurons, where they function
as receptors important for neuronal-cell recognition.
Such a complicated pattern of splicing poses a sig-
nificant challenge to prediction of the functional con-
sequences of putative pathogenic mutations. For most
genes, the implications of protein-truncating mutations
are relatively easily defined. Loss of critical domains
usually results in either constitutive activation or func-
tional loss. In the case of PKHD1, many of the normal
splicing products are predicted to yield truncated pro-
teins that lack critical domains, including the TM region
and cytoplasmic tail of polyductin. Similar outcomes
are predicted for many of the mutations described
herein, yet the diseases caused by these mutations are
a de facto bioassay for normal polyductin function. We
suggest two potential explanations to reconcile these
findings. First, all of the observed mutations are pre-
dicted to alter the sequence of the largest ORF. This
may suggest that a critical amount of the full-length
protein is necessary for normal function. A second, al-
ternative possibility is that mutations disrupt a critical
functional stoichiometric or temporal balance between
the different protein products that is normally main-
tained by elaborate, tightly regulated splicing patterns.
The data of northern blot analysis suggest that
PKHD1 is predominantly expressed in the kidney, con-
sistent with the observed phenotype in ARPKD. Much
lower transcript expression was detected in liver—not
an unexpected finding, given that biliary ductules,which
are abnormal in ARPKD, constitute only a small frac-
tion of the total tissue. The human fetal expression pat-
tern of PKHD1 is consistent with both the observation
that renal and hepatic abnormalities develop in utero
and the hypothesis that disease pathogenesis involves a
defect in terminal epithelial differentiation (Calvet
1993). Continued expression of PKHD1 in human tis-
sues suggests an additional, undefined role for its gene
product in mature, terminally differentiated organs.
PKHD1 expression slightly greater than that observed
in the liver was also observed in the pancreas. A disease-
associated phenotype has not been described in this or-
gan. This situation is not dissimilar to that found in
dominant polycystic kidney disease, in which pancreatic
cysts were an underappreciated manifestation of the dis-
ease until the role of the polycystin genes in pancreatic
development became apparent on the basis of mouse
studies (Lu et al. 1997; Wu et al. 1998). Pancreatic cysts
do not result in clinical symptoms in dominant poly-
cystic disease (Nicolau al. 2000).
We propose that the transcript with the longest ORF
is the likeliest gene product of PKHD1, since it is the
only transcript that would be altered by all of the mu-
tations that we have described. The product that it is
predicted to encode, polyductin, shares some structural
features with both the Ron class of tyrosine kinase re-
ceptors and the plexin superfamily and thus may also
function to regulate either cell-cell recognition or cell
motility. However, the PKHD1-gene product(s) lacks
key structural elements of these protein classes, sug-
gesting that its mechanism of action will differ from
that seen in the other classes. The presence of multiple
PbH1 repeats in polyductin suggests a possible role for
this molecule in carbohydrate recognition and modifi-
cation. Targets for binding could include carbohydrate
moieties present either in glycoproteins on the cell sur-
face or in the matrix of the basement membrane; in-
teractions with polyductin may modulate cell-cell or
cell-matrix attachments. One intriguing possibility is
that the variable number of IPT and PbH1 domains
encoded by some of the shorter transcripts could po-
tentially result in products with different specificities or
binding affinities for target factors, as has been postu-
lated for the neurexins (Missler and Sudhof 1998). We
presently are unable to determine whether polyductin
serves primarily as a receptor, ligand, or membrane-
associated enzyme.
Polyductin has a unique combination of structural
features not previously observed in a single molecule.
The discovery of a second protein, D86, with a very
similar pattern suggests that the gene products of the
D86 and PKHD1 loci may be prototypes of a novel
class of proteins. From a structural perspective, D86 is
most similar to the polyductin-S family of polypeptides.
By analogy with polyductin, we propose the possible
existence of a larger, membrane-associated form ofD86.
The fact that D86 is described as a secreted protein
further supports our hypothesis that polyductin-S may
have the same properties.
We have identified the gene responsible for ARPKD
and have determined that it is a novel, large, and com-
plex gene. Although this complexity may pose some
challenges with respect to the implementation of DNA-
based diagnostic testing, the discovery of PKHD1
should provide important biologic insights into epithe-
lial differentiation and organogenesis. In addition, these
new insights should help to establish a platform for
development of targeted therapeutic interventions for
patients with this often devastating disease.
Note added in proof.—Since submission of this ar-
ticle, another group has reported similar findings (Ward
et al. 2002). In that publication, the PKHD1-gene prod-
uct described is essentially identical, in both size and
sequence, to polyductin and was named “fibrocystin.”
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